Literature DB >> 31012125

Comparison of preoperative locoregional Ga-68 PSMA-11 PET-CT and mp-MRI results with postoperative histopathology of prostate cancer.

Burcak Yilmaz1, Rustu Turkay2, Yunus Colakoglu3, Halil F Baytekin4, Nurhan Ergul1, Selcuk Sahin3, Volkan Tugcu3, Ercan Inci2, Ali I Tasci3, Tevfik F Cermik1.   

Abstract

BACKGROUND: Conventional imaging modalities are inadequate to evaluate locoregional extension of prostate cancer (PCa). The aim of the current retrospective study was to investigate the diagnostic efficacy of Gallium-68 prostate-specific membrane antigen-11 (Ga-68 PSMA-11) positron emission tomography/computed tomography (PET/CT) and multiparametric magnetic resonance imaging (mp-MRI) for staging preoperative PCa patients with correlating histopathology.
MATERIALS AND METHODS: Twenty-four patients with histologically proven PCa underwent both Ga-68 PSMA-11 PET/CT and mp-MRI before robot-assisted laparoscopic radical prostatectomy. For each tumor area, correlations with histopathological results were defined for tumor localization, extraprostatic extension (EPE) of the tumor, invasion of seminal vesicle (SVI) and bladder neck invasion (BNI). In patients with regional lymph node (LN) dissection, histopathological results were also correlated with imaging modalities.
RESULTS: Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for detection of EPE and SVI were higher for mp-MRI than Ga-68 PSMA-11 PET/CT. On the other hand Ga-68 PSMA-11 PET/CT had significant successful results for detection of LN metastases when compared with mp-MRI. But for BNI detection both modalities had same insufficient results. Ga-68 PSMA-11 PET/CT had strong results for appropriate tumor localization in the gland.
CONCLUSION: Ga-68 PSMA PET/CT has superior results for assessing local LN metastases and for intraprostatic tumor localization. Whereas, mp-MRI must be the preferred modality for determining SVI and EPE. But both imaging modalities failed for determining BNI accurately. Both modalities should be used in conjunction with each other for better treatment planning.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Gallium-68 prostate-specific membrane antigen-11 positron emission tomography/computed tomography; extraprostatic extension; lymph node; multiparametric magnetic resonance imaging; prostate cancer; seminal vesicle

Mesh:

Substances:

Year:  2019        PMID: 31012125     DOI: 10.1002/pros.23812

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Efficacy of 68Ga-PSMA-11 PET/CT with biparametric MRI in diagnosing prostate cancer and predicting risk stratification: a comparative study.

Authors:  Yi Nuo; Aimei Li; Lulu Yang; Hailin Xue; Feng Wang; Liwei Wang
Journal:  Quant Imaging Med Surg       Date:  2022-01

2.  99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.

Authors:  Burçak Yılmaz; Selçuk Şahin; Nurhan Ergül; Yunus Çolakoğlu; Halil Fırat Baytekin; Doğukan Sökmen; Volkan Tuğcu; Ali İhsan Taşçı; Tevfik Fikret Çermik
Journal:  Ann Nucl Med       Date:  2022-04-15       Impact factor: 2.668

3.  The Diagnostic Value of High-Resolution Computed Tomography Features Combined with Mycoplasma Pneumoniae Ribonucleic Acid Load Detection for Refractory Mycoplasma Pneumonia.

Authors:  Hongping Wei; Chunyan Wang; Lili Ding; Min Wu
Journal:  Contrast Media Mol Imaging       Date:  2022-05-04       Impact factor: 3.009

Review 4.  Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.

Authors:  Henk B Luiting; Pim J van Leeuwen; Martijn B Busstra; Tessa Brabander; Henk G van der Poel; Maarten L Donswijk; André N Vis; Louise Emmett; Phillip D Stricker; Monique J Roobol
Journal:  BJU Int       Date:  2019-11-29       Impact factor: 5.588

5.  Head-to-Head Comparison of 68Ga-PSMA-11 PET/CT and Multiparametric MRI for Pelvic Lymph Node Staging Prior to Radical Prostatectomy in Patients With Intermediate to High-Risk Prostate Cancer: A Meta-Analysis.

Authors:  Xueju Wang; Qiang Wen; Haishan Zhang; Bin Ji
Journal:  Front Oncol       Date:  2021-10-20       Impact factor: 6.244

6.  Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients.

Authors:  Riccardo Laudicella; Stephan Skawran; Daniela A Ferraro; Urs J Mühlematter; Alexander Maurer; Hannes Grünig; Hendrik J Rüschoff; Niels Rupp; Olivio Donati; Daniel Eberli; Irene A Burger
Journal:  Insights Imaging       Date:  2022-04-15

7.  Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer.

Authors:  Jung Kwon Kim; Yoo Sung Song; Won Woo Lee; Hak Jong Lee; Sung Il Hwang; Sung Kyu Hong
Journal:  Prostate Int       Date:  2022-04-29

8.  Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.

Authors:  Sungmin Woo; Soleen Ghafoor; Anton S Becker; Sangwon Han; Andreas G Wibmer; Hedvig Hricak; Irene A Burger; Heiko Schöder; Hebert Alberto Vargas
Journal:  Eur J Hybrid Imaging       Date:  2020-09-09

9.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.

Authors:  Lars J Petersen; Helle D Zacho
Journal:  Cancer Imaging       Date:  2020-01-23       Impact factor: 3.909

10.  Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis.

Authors:  Lei Peng; Jinze Li; Chunyang Meng; Jinming Li; Chengyu You; Dandan Tang; Tangqiang Wei; Wei Xiong; Yunxiang Li
Journal:  Radiat Oncol       Date:  2020-10-01       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.